期刊文献+

白细胞介素-2对allo-HSCT后白血病早期复发患者治疗效果的临床研究 被引量:1

下载PDF
导出
摘要 目的观察白细胞介素-2(IL-2)对异基因造血干细胞移植术(allo-HSCT)后白血病早期复发患者的治疗效果。方法 2010年6月~2011年6月,本科共对14例allo-HSCT后复发的患者给予IL-2治疗,观察其临床疗效及并发症。结果 13名患者随访13~24月(中位时间18月),未出现本病全面复发,无病生存率为92.85%。GVHD的表现均为Ⅰ度,发生率为35.7%。结论 IL-2是治疗allo-HSCT后早期复发的有效且重要的方法,取得了较好的疗效,且治疗后GVHD的发生率低、表现较轻。
出处 《中国输血杂志》 CAS CSCD 北大核心 2013年第3期123-125,共3页 Chinese Journal of Blood Transfusion
  • 相关文献

参考文献9

  • 1Sehleuning M. Adoptive allogeneie immunotherapy-history and fu- ture perspectives. Transfus Sci ,2000,23 (2) : 133-150.
  • 2Sykes M, Harty MW, Szot GL. Intedeukin-2 inhibits graft-versus- host disease-promoting activity of CIM cells while preserving CIM- and CD8- mediated graft-versus-leukemia effects. Blood 1994,83 (9) :2560-2569.
  • 3Slavin S,Naparstek E, Nagler A,et al. Allogeneic cell therapy with donor peripheral blood ceils and recombinant human 1L-2 to treat leukemia relapse after allogeneic BMT. Blood 1996,87 ( 6 ) : 2195- 2004.
  • 4Nadala E, Fowlerb A, Kanfera E, et al. Adjuvant interleukin-2 ther- apy for patients refractory to donor lymphocyte infusions. Exp He- matol 2004,32(2) :218-233.
  • 5Sullivan KM, Storb R, Buekner CD, et al. Graft-versus-host-disease as adoptive immunotherapy in paitients with advanced hematologic neoplasms. N Engl J Med, 1989,320( 13 ) :828-834.
  • 6Avigan D, Wu Z, Joyce R, et al. Immune reconstitution following high-dose chemotherapy with stem eel] rescue in patients with ad- vancecl breast cancer. Bone Marrow Transplant,2000,26 (2) : 169- 176.
  • 7Liu KY, Chen YH,Liu DH, et al. A pilot study of low-dose recombi- nant Interleukin-2 for acute lymphoblastic malignancy after unma- nipuhted allogeneic blood and marrow transplantation. Bone MarrowTransplant ,2008,42:535-539.
  • 8刘德亮,丁家华.白细胞介素-2预防急性淋巴细胞白血病异基因造血干细胞移植术后复发的临床研究[J].临床血液学杂志,2012,25(1):39-42. 被引量:1
  • 9Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single dose and relapse after aUografting for chronic mydoid leukemia. Blood, 2005,95( 1 ) :67-71.

二级参考文献13

  • 1GUZMAN M L,JORDAN C T. Considerations for targeting malignant stem cells in leukemia[J]. Cancer Control,2004,11:97--104.
  • 2SZNOL M, PARKINSON D R. Interleukin-2 in therapy of hematologic malignancies[J].Blood, 1994,83 : 2020 -- 2020.
  • 3SYKES M, HARTY M W, SZOT C L, et al. Interleukin- 2 inhibits graft-versus-host diseasepromoting activity of CD4+ cells while preserving CIN- and CD8-mediated graft-versusleukemia effects[J]. Blood, 1994,83 : 2560 --2560.
  • 4NORDLANDER A, MATTSSON J, RINGDEN O, et al. Graft-versus-host disease is associated with a lower re- lapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia[J].Biol Blood Marrow Transplant, 2004,10 : 195 -- 200.
  • 5DAZZI F, SZYDLO R M,CRADDOCK C,et al. Comparison of single dose and escalating dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia[J]. Blood, 2000,95 : 67-- 71.
  • 6KIM D H, KIM J G, LEE N Y, et al. Risk factors for late cytomegalovirus,infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection[J]. Bone Marrow Transplant, 2004, 34 : 21 -- 25.
  • 7LIN P C,HSIAO L T,CHEN P M. Acute polymyositis after donor lymphocyte infusion [J]. Eur J Haentatol, 2005,74 : 166-- 172.
  • 8ROBINSON N,SANDERS J E,BENYUNES M C,et al. Phase I trial of interleukin-2 after unmodified HLA- matched sibling bone marrow transplantation for children with acute leukemia[J]. Blood, 1996,87 : 1249-- 1254.
  • 9LIU K Y,CHEN Y H,LIU D H,et al. A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation[J].Bone Marrow Transplant, 2008,42..535--539.
  • 10SICA S, LAURENTI L, SORA F,.et al. Lummune reconstitution following transplantation of autologous peripheral CD34+cells[J]. Acta Haematol, 2001,105 : 179 -187.

同被引文献10

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部